| HER3 signaling and targeted therapy in cancer R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Oncology reviews 12 (1), 2018 | 193 | 2018 |
| PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects JTG R Mishra, H Patel, S Alanazi, MK Kilroy International Journal of Molecular Sciences 22 (7), 3464, 2021 | 153 | 2021 |
| Osteopontin as a therapeutic target for cancer M Bandopadhyay, A Bulbule, R Butti, G Chakraborty, P Ghorpade, ... Expert opinion on therapeutic targets 18 (8), 883-895, 2014 | 145 | 2014 |
| Current advances in the treatment of BRAF-mutant melanoma H Patel, N Yacoub, R Mishra, A White, L Yuan, S Alanazi, JT Garrett Cancers 12 (2), 482, 2020 | 144 | 2020 |
| Genomic alterations of ERBB receptors in cancer: clinical implications R Mishra, AB Hanker, JT Garrett Oncotarget 8 (69), 114371, 2017 | 120 | 2017 |
| Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model G Chakraborty, S Kumar, R Mishra, TV Patil, GC Kundu PloS one 7 (3), e33633, 2012 | 96 | 2012 |
| Osteopontin: a potentially important therapeutic target in cancer M Ahmed, R Behera, G Chakraborty, S Jain, V Kumar, P Sharma, ... Expert opinion on therapeutic targets 15 (9), 1113-1126, 2011 | 86 | 2011 |
| Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression G Chakraborty, S Jain, S Kale, R Raja, S Kumar, R Mishra, GC Kundu Molecular Medicine Reports 1 (5), 641-646, 2008 | 69 | 2008 |
| Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis R Mishra, D Thorat, G Soundararajan, SJ Pradhan, G Chakraborty, ... Oncogene 34 (12), 1584-1595, 2015 | 62 | 2015 |
| Quercetin and sulforaphane in combination suppress the progression of melanoma through the down‑regulation of matrix metalloproteinase-9 SJ Pradhan, R Mishra, P Sharma, GC Kundu Experimental and therapeutic medicine 1 (6), 915-920, 2010 | 59 | 2010 |
| BRAF mutant melanoma adjusts to BRAF/MEK inhibitors via dependence on increased antioxidant SOD2 and increased reactive oxygen species levels L Yuan, R Mishra, H Patel, S Alanazi, X Wei, Z Ma, JT Garrett Cancers 12 (6), 1661, 2020 | 28 | 2020 |
| Activating HER3 mutations in breast cancer JTG R Mishra, S Alanazi, L Yuan, T Solomon, TM Thaker, N Jura Oncotarget 9 (45), 27773-27788, 2018 | 28 | 2018 |
| Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma JTG Long Yuan1, Rosalin Mishra1, Hima Patel1, Safnas Abdulsalam2, Kenneth D ... Journal of Cancer 9 (24), 4665-4676, 2018 | 25 | 2018 |
| IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma JTG H Patel,R Mishra,Yacoub N, S Alanazi,MK Kilroy Cancers 13 (22), 5863, 2021 | 20 | 2021 |
| The potential of class 3 semaphorins as both targets and therapeutics in cancer R Mishra, D Kumar, D Tomar, G Chakraborty, S Kumar, GC Kundu Expert Opinion on Therapeutic Targets 19 (3), 427-442, 2015 | 18 | 2015 |
| Phosphoinositide 3-Kinase (PI3K) reactive oxygen species (ROS)-activated prodrug in combination with anthracycline impairs pi3k signaling, increases DNA damage response and … R Mishra, L Yuan, H Patel, AS Karve, H Zhu, A White, S Alanazi, P Desai, ... International Journal of Molecular Sciences 22 (4), 2088, 2021 | 13 | 2021 |
| Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics H Zhu, R Mishra, L Yuan, SF Abdul Salam, J Liu, G Gray, AD Sterling, ... ChemMedChem 14 (22), 1933-1939, 2019 | 9 | 2019 |
| Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma JTG R Mishra, H Patel, L Yuan Cancer Research Frontiers. 4 (1), 101-130, 2018 | 7 | 2018 |
| HER3 alterations in cancer and potential clinical implications MK Kilroy, SY Park, W Feroz, H Patel, R Mishra, S Alanazi, JT Garrett Cancers 14 (24), 6174, 2022 | 4 | 2022 |
| RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells H Patel, R Mishra, A Wier, N Mokhtarpour, EJ Merino, JT Garrett Anti-Cancer Drugs 34 (4), 519-531, 2023 | 2 | 2023 |
